MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.

The frequent overexpression of CD46 in malignant tumors has provided a basis to use vaccine-lineage measles virus (MeV) as an oncolytic virotherapy platform. However, widespread measles seropositivity limits the systemic deployment of oncolytic MeV for the treatment of metastatic neoplasia. Here, we...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Miguel Ángel Muñoz-Alía, Rebecca A Nace, Alexander Tischer, Lianwen Zhang, Eugene S Bah, Matthew Auton, Stephen J Russell
Format: Artykuł
Język:English
Wydane: Public Library of Science (PLoS) 2021-02-01
Seria:PLoS Pathogens
Dostęp online:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009283&type=printable

Podobne zapisy